2.96
0.03 (1.02%)
| Previous Close | 2.93 |
| Open | 2.95 |
| Volume | 560,546 |
| Avg. Volume (3M) | 1,337,814 |
| Market Cap | 195,729,472 |
| Price / Sales | 1.17 |
| Price / Book | 6.50 |
| 52 Weeks Range | |
| Earnings Date | 4 Nov 2025 |
| Profit Margin | -54.23% |
| Operating Margin (TTM) | -34.45% |
| Diluted EPS (TTM) | -1.32 |
| Quarterly Revenue Growth (YOY) | 83.60% |
| Total Debt/Equity (MRQ) | 208.79% |
| Current Ratio (MRQ) | 2.44 |
| Operating Cash Flow (TTM) | -35.98 M |
| Levered Free Cash Flow (TTM) | -21.69 M |
| Return on Assets (TTM) | -19.38% |
| Return on Equity (TTM) | -144.50% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Mixed |
| Medical Devices (Global) | Mixed | Bearish | |
| Stock | Neuronetics, Inc. | Bearish | Bullish |
AIStockmoo Score
| Analyst Consensus | -2.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 1.5 |
| Technical Oscillators | -2.5 |
| Average | -1.25 |
|
Neuronetics Inc a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulations, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advanced Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address many of the key limitations of existing treatment options. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Small Value |
| % Held by Insiders | 9.17% |
| % Held by Institutions | 62.81% |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 04 Nov 2025 | Announcement | Neuronetics Reports Third Quarter 2025 Financial and Operating Results and Announces CEO Transition Plan |
| 31 Oct 2025 | Announcement | Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) |
| 30 Oct 2025 | Announcement | Neuronetics Announces Three-Year Exclusive Partnership with Elite DNA Behavioral Health to Expand NeuroStar Access and Operational Excellence |
| 21 Oct 2025 | Announcement | Neuronetics to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call |
| 17 Sep 2025 | Announcement | New York State Medicaid Expands Coverage for TMS Therapy, Including NeuroStar® Advanced Therapy, to Treat Major Depressive Disorder (MDD) |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |